Cell Biochemistry and Biophysics

, Volume 71, Issue 1, pp 481–489 | Cite as

Heat Shock Protein 90 Stimulates Rat Mesenchymal Stem Cell Migration via PI3K/Akt and ERK1/2 Pathways

  • Feng Gao
  • Xinyang Hu
  • Xiaojie Xie
  • Xianbao Liu
  • Jianan WangEmail author
Original Paper


The objective of this study was to determine the role of Hsp90α in regulating the migration of mesenchymal stem cells (MSCs) and to investigate the underlying mechanisms of this effect. MSCs migration was assessed by wound healing assay and transwell migration assay. Hsp90α expression was silenced in MSC by siRNA (sirHsp90α). The activity of secreted metalloproteases MMP-2 and MMP-9, and their expression levels in MSC were evaluated using gelatin zymography, Western blot analysis and real-time PCR. Gene expression of VCAM-1 and CXCR4 cytokines was evaluated by real-time PCR. Akt and ERK activity were analyzed by Western blotting using antibodies against phosphorylated forms of these proteins. Treatment with Hsp90α significantly enhanced MSC migration, and this effect was blocked by transfecting MSC with sirHsp90α. Treating the cells with recombinant human Hsp90α (rhHsp90α) enhanced gene expression and protein levels of MMP-2 and MMP-9, as well as their secretion and activity. MSC incubated with rhHsp90α exhibited increased gene expression of CXCR4 and VCAM-1. Finally, the levels of phosphorylated Akt and Erk were markedly increased by rhHsp90α treatment. These findings indicate that Hsp90α promotes MSCs migration via PI3K/Akt and ERK signaling pathways, and that this effect is possibly mediated by MMPs, SDF-1/CXCR4 pathway, and VCAM-1.


Heat shock protein Mesenchymal stem cell Migration Cytokines 



This project was supported by the National Natural Science Foundation of China (Nos. 30670868, 30770887, and 30770887/H0220), the Traditional Chinese Medicine of Zhejiang Province (No. 2014ZA005), and the Zhejiang Provincial Natural Science foundation of China (Y2100362) and Science Technology Department of Zhejiang Province (2010R10G2010160). China.


  1. 1.
    Majumdar, M. K., Thiede, M. A., Haynesworth, S. E., Bruder, S. P., & Gerson, S. L. (2000). Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. Journal of Hematotherapy & Stem Cell Research, 9(6), 841–848.CrossRefGoogle Scholar
  2. 2.
    Wright, V., Peng, H., Usas, A., et al. (2002). BMP4-expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. Molecular Therapy, 6(2), 169–178.PubMedCrossRefGoogle Scholar
  3. 3.
    Mizuno, K., Muneta, T., Morito, T., et al. (2008). Exogenous synovial stem cells adhere to defect of meniscus and differentiate into cartilage cells. Journal of Medical and Dental Sciences, 55(1), 101–111.PubMedGoogle Scholar
  4. 4.
    Li, Y., Yu, J., Li, M., Qu, Z., & Ruan, Q. (2011). Mouse mesenchymal stem cells from bone marrow differentiate into smooth muscle cells by induction of plaque-derived smooth muscle cells. Life Sciences, 88(3–4), 130–140.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang, Q. W., Chen, Z. L., & Piao, Y. J. (2005). Mesenchymal stem cells differentiate into tenocytes by bone morphogenetic protein (BMP) 12 gene transfer. Journal of Bioscience and Bioengineering, 100(4), 418–422.PubMedCrossRefGoogle Scholar
  6. 6.
    Elabd, C., Chiellini, C., Carmona, M., et al. (2009). Human multipotent adipose-derived stem cells differentiate into functional brown adipocytes. Stem Cells, 27(11), 2753–2760.PubMedCrossRefGoogle Scholar
  7. 7.
    Psaltis, P. J., Zannettino, A. C., Worthley, S. G., & Gronthos, S. (2008). Concise review: Mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells, 26(9), 2201–2210.PubMedCrossRefGoogle Scholar
  8. 8.
    Marenzi, G., & Bartorelli, A. L. (2007). Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. European Heart Journal, 28(17), 2172–2173. author reply 2173–2174.PubMedCrossRefGoogle Scholar
  9. 9.
    Fuh, E., & Brinton, T. J. (2009). Bone marrow stem cells for the treatment of ischemic heart disease: A clinical trial review. Journal of Cardiovascular Translational Research, 2(2), 202–218.PubMedCrossRefGoogle Scholar
  10. 10.
    Barbash, I. M., Chouraqui, P., Baron, J., et al. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation, 108(7), 863–868.PubMedCrossRefGoogle Scholar
  11. 11.
    Langer, T., Rosmus, S., & Fasold, H. (2003). Intracellular localization of the 90 kDA heat shock protein (HSP90alpha) determined by expression of a EGFP-HSP90alpha-fusion protein in unstressed and heat stressed 3T3 cells. Cell Biology International, 27(1), 47–52.PubMedCrossRefGoogle Scholar
  12. 12.
    Yano, A., Tsutsumi, S., Soga, S., et al. (2008). Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proceedings of the National Academy of Sciences of the United States of America, 105(40), 15541–15546.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Wu, L. X., Xu, J. H., Huang, X. W., Zhang, K. Z., Wen, C. X., & Chen, Y. Z. (2006). Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90. Acta Pharmacologica Sinica, 27(6), 694–699.PubMedCrossRefGoogle Scholar
  14. 14.
    Zsebik, B., Citri, A., Isola, J., Yarden, Y., Szollosi, J., & Vereb, G. (2006). Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunology Letters, 104(1–2), 146–155.PubMedCrossRefGoogle Scholar
  15. 15.
    Giaccone, G., & Rajan, A. (2009). Met amplification and HSP90 inhibitors. Cell Cycle, 8(17), 2682.PubMedCrossRefGoogle Scholar
  16. 16.
    Grammatikakis, N., Lin, J. H., Grammatikakis, A., Tsichlis, P. N., & Cochran, B. H. (1999). p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Molecular and Cellular Biology, 19(3), 1661–1672.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Sidera, K., Gaitanou, M., Stellas, D., Matsas, R., & Patsavoudi, E. (2008). A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. Journal of Biological Chemistry, 283(4), 2031–2041.PubMedCrossRefGoogle Scholar
  18. 18.
    Tsutsumi, S., Scroggins, B., Koga, F., et al. (2008). A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene, 27(17), 2478–2487.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Gao, F., Hu, X. Y., Xie, X. J., et al. (2010). Heat shock protein 90 protects rat mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis via the PI3K/Akt and ERK1/2 pathways. Journal of Zhejiang University-Science B, 11(8), 608–617.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Xie, X. J., Wang, J. A., Cao, J., & Zhang, X. (2006). Differentiation of bone marrow mesenchymal stem cells induced by myocardial medium under hypoxic conditions. Acta Pharmacologica Sinica, 27(9), 1153–1158.PubMedCrossRefGoogle Scholar
  21. 21.
    Heussen, C., & Dowdle, E. B. (1980). Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Analytical Biochemistry, 102(1), 196–202.PubMedCrossRefGoogle Scholar
  22. 22.
    Baer, P. C., & Geiger, H. (2010). Mesenchymal stem cell interactions with growth factors on kidney repair. Current Opinion in Nephrology and Hypertension, 19(1), 1–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Walsh, D., Li, Z., Wu, Y., & Nagata, K. (1997). Heat shock and the role of the HSPs during neural plate induction in early mammalian CNS and brain development. Cellular and Molecular Life Sciences, 53(2), 198–211.PubMedCrossRefGoogle Scholar
  24. 24.
    Lesko, E., Gozdzik, J., Kijowski, J., Jenner, B., Wiecha, O., & Majka, M. (2007). HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anti-Cancer Drugs, 18(10), 1173–1181.PubMedCrossRefGoogle Scholar
  25. 25.
    Minami, Y., Kawasaki, H., Miyata, Y., Suzuki, K., & Yahara, I. (1991). Analysis of native forms and isoform compositions of the mouse 90-kDa heat shock protein, HSP90. Journal of Biological Chemistry, 266(16), 10099–10103.PubMedGoogle Scholar
  26. 26.
    Nemoto, T., & Sato, N. (1998). Oligomeric forms of the 90-kDa heat shock protein. Biochemical Journal, 330(Pt 2), 989–995.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Grenert, J. P., Sullivan, W. P., Fadden, P., et al. (1997). The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. Journal of Biological Chemistry, 272(38), 23843–23850.PubMedCrossRefGoogle Scholar
  28. 28.
    Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., & Rosen, N. (2002). Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. Journal of Biological Chemistry, 277(42), 39858–39866.PubMedCrossRefGoogle Scholar
  29. 29.
    Roe, S. M., Ali, M. M., Meyer, P., et al. (2004). The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell, 116(1), 87–98.PubMedCrossRefGoogle Scholar
  30. 30.
    Sato, S., Fujita, N., & Tsuruo, T. (2000). Modulation of Akt kinase activity by binding to Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 97(20), 10832–10837.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Abi-Younes, S., Sauty, A., et al. (2000). The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circulation Research, 86(2), 131–138.PubMedCrossRefGoogle Scholar
  32. 32.
    Yamaguchi, J., Kusano, K. F., et al. (2003). Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation, 107(9), 1322–1328.PubMedCrossRefGoogle Scholar
  33. 33.
    Oberlin, E., Amara, A., et al. (1996). The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature, 382(6594), 833–835.PubMedCrossRefGoogle Scholar
  34. 34.
    Jo, D. Y., Rafii, S., et al. (2000). Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. Journal of Clinical Investigation, 105(1), 101–111.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Lima e Silva, R., Shen, J., et al. (2007). The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization. FASEB Journal, 21(12), 3219–3230.PubMedCrossRefGoogle Scholar
  36. 36.
    Abbott, J. D., Huang, Y., et al. (2004). Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation, 110(21), 3300–3305.PubMedCrossRefGoogle Scholar
  37. 37.
    Guo, Y., Hangoc, G., et al. (2005). SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells, 23(9), 1324–1332.PubMedCrossRefGoogle Scholar
  38. 38.
    Shao, H., Tan, Y., et al. (2008). Statin and stromal cell-derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells, 26(5), 1376–1384.PubMedCrossRefGoogle Scholar
  39. 39.
    Hyun, Y. M., Chung, H. L., et al. (2009). Activated integrin VLA-4 localizes to the lamellipodia and mediates T cell migration on VCAM-1. The Journal of Immunology, 183(1), 359–369.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Bowden, R. A., Ding, Z. M., et al. (2002). Role of alpha4 integrin and VCAM-1 in CD18-independent neutrophil migration across mouse cardiac endothelium. Circulation Research, 90(5), 562–569.PubMedCrossRefGoogle Scholar
  41. 41.
    Matsuura, K., Honda, A., et al. (2009). Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. Journal of Clinical Investigation, 119(8), 2204–2217.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Lu, L., Zhang, J. Q., et al. (2004). Molecular and cellular events at the site of myocardial infarction: from the perspective of rebuilding myocardial tissue. Biochemical and Biophysical Research Communications, 320(3), 907–913.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Feng Gao
    • 1
    • 2
    • 3
  • Xinyang Hu
    • 1
    • 2
  • Xiaojie Xie
    • 1
    • 2
  • Xianbao Liu
    • 1
    • 2
  • Jianan Wang
    • 1
    • 2
    Email author
  1. 1.Department of Cardiology, Second Affiliated HospitalZhejiang University College of MedicineHangzhouPeople’s Republic of China
  2. 2.Cardiovascular Key Laboratory of Zhejiang Province, Second Affiliated HospitalZhejiang University College of MedicineHangzhouPeople’s Republic of China
  3. 3.Department of CardiologyZhejiang Provincial People’s HospitalHangzhouPeople’s Republic of China

Personalised recommendations